Nwam LLC Takes Position in Edwards Lifesciences Co. (NYSE:EW)

Nwam LLC purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,568 shares of the medical research company’s stock, valued at approximately $697,000.

A number of other hedge funds have also recently added to or reduced their stakes in EW. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $29,000. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at $32,000. Avior Wealth Management LLC boosted its position in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares in the last quarter. Webster Bank N. A. acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth $39,000. Finally, Peoples Bank KS purchased a new position in shares of Edwards Lifesciences in the 3rd quarter valued at about $40,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.1 %

Shares of EW opened at $70.48 on Friday. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The firm has a market capitalization of $41.57 billion, a P/E ratio of 10.17, a price-to-earnings-growth ratio of 3.96 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock’s fifty day simple moving average is $67.70 and its 200 day simple moving average is $75.66.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same period last year, the business posted $0.59 EPS. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Robert W. Baird decreased their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Evercore ISI lowered their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Barclays dropped their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Morgan Stanley reiterated an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. Finally, Royal Bank of Canada dropped their price target on Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $75.67.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. The trade was a 9.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 40,000 shares of company stock valued at $2,657,000 over the last 90 days. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.